Inotiv, Inc.

  • Market Cap: Micro Cap
  • Industry: Miscellaneous
  • ISIN: US45783Q1004
USD
0.88
0.01 (1.07%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Inotiv, Inc. stock-summary
stock-summary
Inotiv, Inc.
Miscellaneous
Bioanalytical systems, Inc. is an international contract research company providing drug discovery and development services and analytical instruments. The Company operates in two segments: contract research services and research products. The contract research services segment provides research and development support on a contract basis to pharmaceutical companies. The research products segment provides liquid chromatography, electrochemical and physiological monitoring products to pharmaceutical companies, universities, government research centers, and medical research institutions. The Company supports the preclinical and clinical development needs of researchers and clinicians for small molecule and large biomolecule drug candidates. The contract research services segment provides screening and pharmacological testing, preclinical safety testing, formulation development, regulatory compliance and quality control testing.
Company Coordinates stock-summary
Company Details
2701 Kent Ave , WEST LAFAYETTE IN : 47906-1350
stock-summary
Tel: 1 317 4634527
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 18 Schemes (12.46%)

Foreign Institutions

Held by 27 Foreign Institutions (2.89%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Dr. Gregory Davis
Interim Chairman of the Board
Mr. Robert Leasure
President, Chief Executive Officer, Director
Dr. John Sagartz
Chief Strategy Officer, Director
Dr. Richard Johnson
Independent Director
Mr. R. Matthew Neff
Independent Director
Ms. Wendy Perrow
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
131 Million
(Quarterly Results - Jun 2025)
Net Profit:
-18 Million
stock-summary
Industry

Miscellaneous

stock-summary
Market cap

USD 55 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

2.78

stock-summary
Return on Equity

-58.49%

stock-summary
Price to Book

0.38